• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Compass Therapeutics Inc.

    8/2/24 4:15:57 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CMPX alert in real time by email
    SC 13G 1 d854024dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Compass Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    20454B104

    (CUSIP Number)

    July 23, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 20454B104

     

     1   

     NAMES OF REPORTING PERSONS

     

     Blackstone Annex Master Fund L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     3,607,287*

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     3,607,287*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,607,287*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     2.6%*

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     PN

     

    *

    Represents beneficial ownership as of August 1, 2024.

     

    2


    CUSIP No. 20454B104

     

     1   

     NAMES OF REPORTING PERSONS

     

     Spruce Street Aggregator L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     4,382,126*

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     4,382,126*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,382,126*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     3.2%*

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     PN

     

    *

    Represents beneficial ownership as of August 1, 2024.

     

    3


    CUSIP No. 20454B104

     

     1   

     NAMES OF REPORTING PERSONS

     

     Blackstone Alternative Asset Management Associates LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     7,989,413*

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     7,989,413*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     7,989,413*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.8%*

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     OO

     

    *

    Represents beneficial ownership as of August 1, 2024.

     

    4


    CUSIP No. 20454B104

     

     1   

     NAMES OF REPORTING PERSONS

     

     Blackstone Holdings II L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     7,989,413*

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     7,989,413*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     7,989,413*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.8%*

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     PN

     

    *

    Represents beneficial ownership as of August 1, 2024.

     

    5


    CUSIP No. 20454B104

     

     1   

     NAMES OF REPORTING PERSONS

     

     Blackstone Holdings I/II GP L.L.C.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     7,989,413*

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     7,989,413*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     7,989,413*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     5.8%*

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     OO

     

    *

    Represents beneficial ownership as of August 1, 2024.

     

    6


    CUSIP No. 20454B104

     

     1   

     NAMES OF REPORTING PERSONS

     

     Blackstone Inc.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     9,495,151*

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     9,495,151*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     9,495,151*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     6.9%*

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     CO

     

    *

    Represents beneficial ownership as of August 1, 2024.

     

    7


    CUSIP No. 20454B104

     

     1   

     NAMES OF REPORTING PERSONS

     

     Blackstone Group Management L.L.C.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     9,495,151*

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     9,495,151*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     9,495,151*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     6.9%*

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     OO

     

    *

    Represents beneficial ownership as of August 1, 2024.

     

    8


    CUSIP No. 20454B104

     

     1   

     NAMES OF REPORTING PERSONS

     

     Stephen A. Schwarzman

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     9,495,151*

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     9,495,151*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     9,495,151*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     6.9%*

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     IN

     

    *

    Represents beneficial ownership as of August 1, 2024.

     

    9


    Item 1(a)

    Name of Issuer:

    Compass Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    80 Guest Street, Suite 601

    Boston, MA 02135

     

    Item 2(a)

    Name of Person Filing:

    This Schedule 13G is being filed by Blackstone Annex Master Fund L.P. (“Annex Fund”), Spruce Street Aggregator L.P. (“Spruce”), Blackstone Alternative Asset Management Associates LLC (“BAAMA”), Blackstone Holdings II L.P. (“Holdings II”), Blackstone Holdings I/II GP L.L.C. (“Holdings GP”), Blackstone Inc. (“Blackstone”), Blackstone Group Management L.L.C. (“Blackstone Management”), and Stephen A. Schwarzman (together with Annex Fund, Spruce, BAAMA, Holdings II, Holdings GP, Blackstone, and Blackstone Management, the “Reporting Persons”).

     

    Item 2(b)

    Address of Principal Business Office or, if None, Residence:

    The principal business address of each of the Reporting Persons is:

    345 Park Avenue, 28th Floor

    New York, NY 10154

     

    Item 2(c)

    Citizenship:

    Annex Fund is a Cayman Islands limited partnership. Spruce is a Cayman Islands exempted limited partnership. BAAMA is a limited liability company organized under the laws of the State of Delaware. Holdings II is a limited partnership organized under the laws of the State of Delaware. Holdings GP is a limited liability company organized under the laws of the State of Delaware. Blackstone is a corporation organized under the laws of the State of Delaware. Blackstone Management is a limited liability company organized under the laws of the State of Delaware. Mr. Schwarzman is a citizen of the United States of America.

     

    Item 2(d)

    Title of Class of Securities:

    Common Stock, $0.0001 par value per share per share (“Common Stock”)

     

    Item 2(e)

    CUSIP Number:

    20454B104

     

    Item 3.

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    Not Applicable.

     

    Item 4.

    Ownership.

    Items 5 through 9 and 11 of each of the cover pages to this Schedule 13G are incorporated herein by reference. Annex Fund holds 3,607,287 shares of Common Stock (the “Annex Fund Shares”) and Spruce holds 4,382,126 shares of Common Stock (the “Spruce Shares”). The Annex Fund Shares and the Spruce Shares represent beneficial ownership of approximately 2.6% and 3.2% of the outstanding shares of Common Stock, respectively. Funds or accounts that may be deemed to be indirectly controlled by a subsidiary of Blackstone Inc. hold an aggregate of 1,505,738 shares of Common Stock representing beneficial ownership of approximately 1.1% of the outstanding shares of Common Stock. Calculations are based on 137,589,171 shares of Common Stock of the Issuer outstanding as of May 10, 2024, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2024.

     

    10


    BAAMA is the general partner of the Annex Fund and Spruce. Holdings II is the sole member of BAAMA. Holdings GP is the general partner of Holdings II. Blackstone is the sole member of Holdings GP. Blackstone Management is the sole holder of the Series II preferred stock of Blackstone. Blackstone Management is wholly owned by its senior managing directors and controlled by its founder, Stephen A. Schwarzman.

    Each Reporting Person may be deemed to beneficially own the Common Stock of the Issuer directly or indirectly controlled by it or him, but neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that any such Reporting Person (other than any Reporting Person to the extent they directly hold Issuer securities) is the beneficial owner of Common Stock of the Issuer referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Act”), or for any other purpose and each of the Reporting Persons expressly disclaims beneficial ownership of such shares of Common Stock. The filing of this statement should not be construed to be an admission that any member of the Reporting Persons are members of a “group” for the purposes of Section 13(d) and 13(g) of the Act.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    11


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    August 2, 2024

     

    BLACKSTONE ANNEX MASTER FUND L.P.
    By: Blackstone Alternative Asset Management Associates LLC, its general partner
    By:  

    /s/ Jack Pitts

      Name:   Jack Pitts
      Title:   Authorized Person

     

    SPRUCE STREET AGGREGATOR L.P.
    By: Blackstone Alternative Asset Management Associates LLC, its general partner
    By:  

    /s/ Jack Pitts

      Name:   Jack Pitts
      Title:   Authorized Person
    BLACKSTONE ALTERNATIVE ASSET MANAGEMENT ASSOCIATES LLC
    By:  

    /s/ Jack Pitts

      Name:   Jack Pitts
      Title:   Authorized Person
    BLACKSTONE HOLDINGS II L.P.
    By: Blackstone Holdings I/II GP L.L.C., its general partner
    By:  

    /s/ Tabea Hsi

      Name:   Tabea Hsi
      Title:   Senior Managing Director
    BLACKSTONE HOLDINGS I/II GP L.L.C.
    By:  

    /s/ Tabea Hsi

      Name:   Tabea Hsi
      Title:   Senior Managing Director
    BLACKSTONE INC.
    By:  

    /s/ Tabea Hsi

      Name:   Tabea Hsi
      Title:   Senior Managing Director


    BLACKSTONE GROUP MANAGEMENT L.L.C.
    By:  

    /s/ Tabea Hsi

      Name:   Tabea Hsi
      Title:   Senior Managing Director

    /s/ Stephen A. Schwarzman

    Stephen A. Schwarzman


    EXHIBIT LIST

     

    Exhibit 99.1    Joint Filing Agreement
    Get the next $CMPX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CMPX

    DatePrice TargetRatingAnalyst
    7/1/2025$9.00Outperform
    Raymond James
    4/2/2025$6.00Market Perform → Outperform
    Leerink Partners
    2/24/2025$12.00Buy
    Guggenheim
    2/19/2025$12.00Overweight
    Piper Sandler
    12/23/2024$32.00Buy
    D. Boral Capital
    11/15/2024$5.00 → $4.00Outperform → Market Perform
    Leerink Partners
    9/16/2024$5.00Neutral → Buy
    Ladenburg Thalmann
    1/31/2023$8.00Buy
    Jefferies
    More analyst ratings

    $CMPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      5/27/25 3:24:21 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Gordon Carl L sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/11/25 7:37:43 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Orbimed Advisors Llc sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/11/25 7:24:24 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      5/27/25 3:24:21 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gen Counsel & Corporate Sec Anderman Jonathan bought $30,800 worth of shares (20,000 units at $1.54), increasing direct ownership by 2,000% to 21,000 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/8/25 9:30:55 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF ACCOUNTING OFFICER Lerner Neil bought $28,400 worth of shares (20,000 units at $1.42), increasing direct ownership by 7% to 320,000 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/8/25 9:25:57 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

      BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. "We are delighted to welcome Barry to Compass during this pivotal and exciting time for the company," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "We have severa

      12/10/24 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Announces CEO Transition

      BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available

      5/28/24 4:10:20 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

      Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half of 2024Continue to enroll in a U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC). Initial data expected in the third quarter of 2023Presented results of a Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers SymposiumExpanded the management team with the appointment of Minori Rosales, M.D. PhD, as Senior Vice President & Head of Clinical DevelopmentAppointed Richard Lindahl, M.B.A., EVP & CFO of Emergent BioSolutio

      5/4/23 8:30:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Financials

    Live finance-specific insights

    See more
    • Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

      Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion. Webinar Details:   Date:  May 04, 2022   Time: 8:00 a.m. ET   Webcast: Registration Link   Replay availability: A replay will be available on the Compass website for 6 months. Abo

      5/3/22 4:01:00 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • OTC Markets Group Announces Quarterly Index Performance and Rebalancing

      NEW YORK, July 20, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX:OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the second quarter 2021 performance and quarterly rebalancing of the OTCQX® and OTCQB® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index. The OTCQX Composite Index (.OTCQX), a benchmark for the overall OTCQX Best Market, was up 3.9% in the second quarter. Ninety-two new companies were added to the index, including: AirBoss of America Corp. (OTCQX:ABSSF); Blackrock Silver Corp. (OTCQX:BKRRF); Belo Sun Mining Corp. (OTCQX:BSXGF); Caldwell Partners International Inc. (OTCQX:CWLPF); Graphite One Inc. (OTCQX:GPHOF)

      7/20/21 4:00:00 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Compass Therapeutics Inc.

      SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      11/14/24 10:00:35 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Compass Therapeutics Inc.

      SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)

      8/2/24 4:15:57 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Compass Therapeutics Inc. (Amendment)

      SC 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      3/22/24 4:59:51 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James resumed coverage on Compass Therapeutics with a new price target

      Raymond James resumed coverage of Compass Therapeutics with a rating of Outperform and set a new price target of $9.00

      7/1/25 8:17:42 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Compass Therapeutics from Market Perform to Outperform and set a new price target of $6.00

      4/2/25 8:43:28 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Compass Therapeutics with a new price target

      Guggenheim initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $12.00

      2/24/25 7:07:23 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

      BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 3-5, 2025. Fireside Chat DetailsDate: Thursday, June 5, 2025Time: 11:05 – 11:35 AM ETWebcast Link: https://wsw.com/webcast/jeff319/cmpx/1867328 Virtual/Replay availability: The fireside chat will be archived for 90 days on Compass' Events page. About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company devel

      5/28/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

      Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting. First patient dosed and actively enrolling patients in an Investigator Sponsored Trial (IST) evaluating tovecimig in patients with BTC in the first-line setting.Successfully completed a pre-IND meeting for CTX-10726 (PD-1 x VEGF-A bispecific antibody), maintaining progress towards expected Q4 2025 IND filing and 2026 clinical data.Advanced the

      5/8/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics to Participate in Upcoming May Investor Events

      BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: The Citizens Life Sciences ConferenceLocation: New York, NYDate: Thursday, May 8, 2025 Time: 1:30 PM ETWebcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592 H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQLocation: New York, NYDate: Tuesday, May 20, 2025 Time: 11:30AM ETWebcast Link: https://journey.ct.events/view/29729b86-5109-46dc-a93b-1cf3

      5/6/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMPX
    SEC Filings

    See more
    • Compass Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Compass Therapeutics, Inc. (0001738021) (Filer)

      6/12/25 4:45:29 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.

      SCHEDULE 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      5/15/25 4:15:24 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Compass Therapeutics Inc.

      10-Q - Compass Therapeutics, Inc. (0001738021) (Filer)

      5/8/25 8:01:09 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care